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Recentpublicationssuggestedthatmonocytesmightbeanattractivecelltypetotransdiﬀerentiateintovariouscellularphenotypes.
Aim was, therefore, to evaluate the potential of blood monocytes to transdiﬀerentiate into osteoblasts. Monocytes isolated from
peripheral blood were subjected to two previously published treatments to obtain unique, multipotent cell fractions, named
programmablecellsofmonocyticorigin(PCMOs)andmonocyte-derivedmesenchymalprogenitorcells(MOMPs).Subsequently,
MOMPs and PCMOs were treated with osteogenic diﬀerentiation medium (including either vitamin D or dexamethasone) for 14
days. Regarding a variety of surface markers, no diﬀerences between MOMPs, PCMOs, and primary monocytes could be detected.
The treatment with osteogenic medium neither resulted in loss of hematopoietic markers nor in adoption of mesenchymal
phenotype in all cell types. No signiﬁcant eﬀect was observed regarding the expression of osteogenic transcription factors, bone-
related genes, or production of mineralized matrix. Osteogenic medium resulted in activation of monocytes and appearance of
osteoclasts. In conclusion, none of the investigated monocyte cell types showed any transdiﬀerentiation characteristics under the
tested circumstances. Based on our data, we rather see an activation and maturation of monocytes towards macrophages and
osteoclasts.
1.Introduction
Full recovery of large bone defects occurring after trauma or
tumor is an unsolved problem in traumatology and ortho-
pedic surgery as such defects can often only be treated in-
suﬃciently with conventional implants. As a consequence,
patients frequently lose their mobility, which results in a loss
of autonomy.
Recently, the concept of tissue engineering for replacing
lost bone has been arousing great interest. In contrast to con-
ventional implants, the engineered tissue construct will be
integrated into the patient’s tissue and replaced by newly
formed bone, allowing entire recovery.
Beside the construction of a scaﬀold mimicking architec-
ture and mechanical properties of the lost bone, the selection
of cells seeded on this scaﬀold is critical. Ideally, cells are
harvested from the patient himself to allow autologous ther-
apy and avoid immunological reactions or transmission of
infectious diseases. Primary bone cells are diﬃcult to isolate
in suﬃcient quantities. Hence, interest has mainly been fo-
cused on stem cells as the source for bone tissue engineering
in the last decade. Multipotent adult stem cells have been
identiﬁed in a number of tissues of the adult organism. They
areresponsibleformaintainingtheintegrityofthetissuethey
reside in. Mesenchymal stem cells in particular have been
proven to have a good potential to diﬀerentiate into osteo-
blasts [1]. They can be isolated from the patient’s bone mar-
row or fat tissue. Nonetheless, harvesting mesenchymal stem
c ellsr eq uir esin vasi v ep r oc ed ur esthatcancausese riousmo r -
bidity [2]. Thus, opening alternative stem cell sources, which2 The Scientiﬁc World Journal
are accessible by less invasive procedures would progress the
whole ﬁeld of regenerative medicine.
In this context, reports about the inherent potential of
peripheral blood monocytes to transdiﬀerentiate into var-
ious cell types other than phagocytes have been increasing
interest. They seem to inhere potential to transdiﬀerentiate
intocellsofallthreegermlayers,namely,endothelial-, osteo-
blast-, chondrocyte-, myoblast-, hepatocyte-, epithelial-,
neuronal-, keratinocyte-, smooth muscle-, pancreatic island-
and adipocyte-like cells [3–8]. Thus, the diﬀerentiation po-
tential of these cells even seems to exceed that of most
adult stem cells. Additionally, autologous monocytes can be
easily isolated by taking a blood sample. This oﬀers great
advantages compared to adult stem cells as source for auto-
logous therapy.
Two diﬀerent methods have mainly been described to
obtain a pluripotent cell fraction from peripheral blood mo-
nocytes. The ﬁrst is the selection of a multipotent sub-
setoftheCD14positivemonocytes—termed“monocyte-de-
rived mesenchymal progenitor cells” (MOMPs)—by culti-
vating them in presence of ﬁbronectin and CD14 negative
blood cells [9]. The alternative approach is a special dedif-
ferentiation procedure, employing M-CSF, IL-3, and beta-
mercaptoethanol, leading to “programmable cells of mono-
cytic origin” (PCMOs) [7]. Both cell types have been shown
to possess the potential for mesenchymal diﬀerentiation.
MOMPswereshowntodiﬀerentiateintoosteoblast-likecells,
producing mineralized matrix and expressing bone markers,
such as alkaline phosphatase, osteocalcin, and bone sialopro-
tein [9]. PCMOs were successfully transdiﬀerentiated into
cells showing a chondrogenic phenotype. If PCMOs were
treated with BMP2, they started expressing collagen type 1,
which may be a hint for inherent potential for osteogenic
transdiﬀerentiation [10].
Concluding, peripheral blood monocytes seem to be a
promising source for bone tissue engineering. The aim of
the present study was to evaluate their potential use for bone
tissue engineering.
2.MaterialsandMethods
2.1. Peptides, Antibodies, and Chemicals. Human recombi-
nant M-CSF, IL-3, and RANKL were acquired from Pepro-
tech (Peprotech, UK), human recombinant Fibronectin and
Collagenase II were obtained from Biochrom (Biochrom,
Germany); Mouse-anti-Human CD68 (DAKO, Denmark),
FITC labeled Mouse-anti-Human CD14, CD45 (Biozol, Ger-
many), APC-labeled Mouse-anti-Human CD90 (BioLegend,
Netherlands), and PE-labeled mouse-anti-human CD105
(southern biotech, USA) antibodies were used; cell culture
medium and supplements were provided by PAA (PAA,
Germany), all other chemicals were obtained from Sigma
(Sigma-Aldrich, Germany).
2.2. Ethical Statement. All used cell types were isolated from
patients undergoing total hip replacement in the Depart-
ment of Traumatology, MRI, Technical University Munich.
The study was approved by the ethics committee of the
faculty of medicine of the Technical University of Munich
(http://www.ek.med.tum.de/, Project Number 2413, TU
Munich, Germany). Patients gave their written consent be-
fore surgery.
2.3. Isolation and Culture of Peripheral Blood Monocytes.
Peripheral blood mononuclear cells were isolated by density
gradient centrifugation with help of LSM 1077 (PAA, Ger-
many) from whole blood. Mononuclear cells (100,000 cells/
cm2) were seeded on uncoated culture ﬂasks and cultured
in presence of RPMI 1640 medium (10% autologous serum,
2mM L-glutamine, 100U/mL penicillin, 100μg/mL strepto-
mycin). After 2h of culture, nonadherent cells were carefully
removed by repetitive washing with PBS.
Adherent cells were further cultivated in uncoated cell
culture ﬂasks in RPMI 1640 culture medium supplemented
with 10% autologous serum, 2mM L-glutamine, 100U/mL
penicillin, and 100μg/mL streptomycin, without addition of
cytokines.
2.4. Selection and Culture of MOMPs. MOMPs were selected
according to the protocol published by Kuwana et al. [9].
Brieﬂy, mononuclear cells (100,000 cells/cm2) were seeded
in ﬁbronectin-coated (10μg/mL) culture ﬂasks and cultured
in presence of DMEM low glucose medium with 10% auto-
logous serum, 2mM L-glutamine, 100U/mL penicillin, and
100μg/mL streptomycin without addition of cytokines. Cells
were cultured for six days with regular change of medium
under avoidance of removal of the nonadherent blood cells.
2.5.DediﬀerentiationofMonocytesintoPCMOsandCultureof
PCMOs. PCMOs were dediﬀerentiated from monocytes ac-
cording to the method published by Ruhnke et al. [7]. This
was modiﬁed in use of autologous serum instead of human
AB-serum [3]. Isolated mononuclear blood cells (100,000
cells/cm2) were seeded in uncoated culture ﬂasks and cul-
tured in presence of RPMI 1640 medium (10% autologous
serum, 2mM L-glutamine, 100U/mL penicillin, 100μg/mL
streptomycin) for two hours. Non-adherent cells were re-
moved by gentle washing with PBS. Adherent cells were cul-
tivated in dediﬀerentiation medium (RPMI 1640 medium,
10% autologous serum, 2mM L-glutamine, 100U/mL peni-
cillin, 100μg/mL streptomycin, 5ng/mL recombinant hu-
man M-CSF, 0.4ng/mL recombinant human IL-3 and
140μM beta-mercaptoethanol) for 6 days. Dediﬀerentiation
medium was replaced every third day.
2.6. Isolation of Primary Human Osteoblasts, Mesenchymal
Stem Cells (MSCs), and Nonadherent Bone Marrow Cells
(naBMCs). As control, primary osteoblasts, MSCs, and
naBMCs were harvested.
For osteoblast isolation, femur heads were processed.
SmallpiecesofcancellousbonewerewashedinPBSandsub-
sequently digested with an equal volume of digestion buﬀer
(PBS, 0.07% Collagenase II) for 1 hour at 37◦C. The treated
bone fragments were placed in osteoblast culture medium
(MEM/Ham’s F12, 10% FCS, 2mM L-glutamine, 100U/mL
penicillin, 100μg/mL streptomycin, 50μM L-ascorbate-2-
phosphate, 50μM beta-glycerol-phosphate) in cell culture
ﬂasks.After7days,thecellsbegantogrowout.AfterreachingThe Scientiﬁc World Journal 3
conﬂuence, the cells were transferred to new cell culture
ﬂasks and expanded.
Isolation of MSCs and naBMCs required bone marrow
which was washed out of cancellous bone with PBS. Mono-
nuclear cells were separated using density gradient cen-
trifugation with help of LSM 1077. Cells were cultured in
DMEM high-glucose medium (10% FCS, 2mM L-gluta-
mine, 100U/mL penicillin, 100μg/mL streptomycin) in un-
coated cell culture dishes. After 48 hours, nonadherent cells
were removed by washing with PBS. The remaining mesen-
chymal stem cells were further cultured and expanded, while
the nonadherent cell fraction (naBMCs) was collected as
control.
2.7. Osteogenic Diﬀerentiation Procedure. Osteogenic diﬀer-
entiation of monocyte-derived cells (MOMPs and PCMOs)
and mesenchymal stem cells (MSCs) was induced by cultiva-
tion in osteogenic medium (culture medium supplemented
with 50μM L-ascorbate-2-phosphate, 10mM beta glycero-
phosphate, and either 100nM dexamethasone or 5μMv i t a -
min D) for 14 days.
For osteogenic stimulation, osteoblasts were cultivated
in osteogenic stimulation medium (DMEM/HAM’s-F12
1:1, 5% FCS, 1% Pen/Strep, 10mM beta-glycerophosphate,
200μM L-ascorbate-2-phosphate, 25mM HEPES, 1.6mM
calciumchloride, 100nM dexamethasone) for 14 days. Oste-
ogenic medium was changed every third day.
2.8. Maturation of Monocytes to Macrophages and Osteo-
clasts. Mononuclear cells were seeded (100,000cells/cm2)i n
uncoated cell culture ﬂasks in RPMI1640 medium supple-
mentedwith10%serum,2mML-glutamine,100U/mLpen-
icillin, and 100μg/mL streptomycin. After 24 hours non-
adherent cells were removed by careful washing with PBS.
Maturation into macrophages was induced by supplemen-
tation of culture medium with 10ng/mL M-CSF for 7 days
[11]. Osteoclasts were obtained by cultivation of monocytes
in presence of20ng/mL RANKL (fromday 1 to 6)and 25ng/
mL M-CSF (from day 6 to 20) [12].
2.9. Alkaline Phosphatase (AP) Activity Assay. After washing
with PBS, cells were incubated with substrate buﬀer (0.2%
4-nitrophenyl-phosphate disodium salt hexahydrate, 50mM
glycine, 1mM MgCl2, 100mM TRIS, pH 10.5) for 1h. For-
mation of 4-nitrophenol (pNP) was determined photomet-
rically at 405nm. Quantiﬁcation was performed using a cali-
bration of pNP. The enzyme activity was either normalized
to cell viability measured by Alamar blue assay according
to the manufacturer’s protocol (Biozol, Germany), or to
relative protein levels determined by Sulforhodamine B
(SRB) staining [13].
2.10. Alizarin Red Staining. After washing twice with PBS,
cells were ﬁxed in 99% ethanol for one hour at −20◦C. Sub-
sequently, the matrix was stained by addition of Alizarin red
(0.5%; pH 4.0) for 10min. Unbound Alizarin red was re-
moved by extensive washing with H2O. Bound Alizarin red
was solved in 10% cetylpyridiumchloride. Alizarin red was
detected photometrically at 562nm and quantiﬁed by a cali-
bration of Alizarin red.
2.11. TRAP Staining. After washing twice with PBS, cells
were ﬁxed with ﬁxation buﬀer (3.1% formaldehyde, 0.2%
Triton X-100 in PBS) for 5min at room temperature. Sub-
sequently, cells were covered with staining buﬀer (0.01%
Naphtol AS-MX Phosphate, 0.06% Fast Red Violet LB Salt,
1% N-N Dimethylformamid, 40mM Na-Acetat, 10mM
Na2-Tartrat, pH 5) for 10min at 37◦C.
2.12. TGF-β,T N F - α, and RANKL Measurement. For mea-
suring of cytokine concentrations, PCMOs were incubated
with serum-free culture medium (RPMI 1640, 2mM L-glu-
tamine) for 48h at 37◦C. TGF-beta levels were measured
by TGF-beta-reporter cells (MFB-F11) [14]. MFB-F11 cells
were cultured for 48h with cell culture supernatants. Result-
ing SEAP activity in the culture supernatant was measured
according to the manufacturer’s instructions with the Great
EscAPe SEAP ﬂuorescent detection kit (Clonetech, France).
TNF-alpha and RANKL levels were measured by ELISA ac-
cording to the manufacturer’s protocol (Peprotech, UK).
The detected signals were normalized to relative protein
levels determined by SRB assay.
2.13. Conventional RT-PCR. Total cellular RNA was iso-
lated with Trifast according to the manufacturer’s protocol
(Peqlab, Germany). First-strand cDNA was synthesized from
1μg RNA according to the manufacturer’s instructions using
the Transcriptor High Fidelity cDNA synthesis kit (Roche,
Germany). Primer sequences and the corresponding anneal-
ing temperatures are summarized in Table 1.P r o d u c t sr e -
solved by gel electrophoresis in a 1.5% (w/v) agarose gel were
visualized with ethidiumbromide. Number of ampliﬁcation
cycles was adjusted for each primer to terminate reaction
in the exponential phase of the PCR. Intensity of bands
was quantiﬁed employing ImageJ software (NIH, USA) and
normalized to GAPDH.
2.14. Immunostaining. Cultured cells were ﬁxed with 4%
formalin for 10min, followed by washing in dH2O. After
this preparation, cells were dried and stored up to 4 weeks
for immunostaining. Immunostaining was performed at
room temperature. First, cells were watered in TRIS buﬀer
for 15min, followed by quenching endogenous peroxidase
activity with 0.3% H2O2 solution for 30min. After extensive
washing with TRIS buﬀer, immunostaining for CD68 was
performed using the DAKO REAL Detection System Per-
oxydase/DAB+ Rabbit/Mouse-Kit (DAKO, Denmark). The
primary CD68-Antibody was used in a dilution of 1:2000.
Counterstaining with haematoxylin was performed addi-
tionally.
2.15. Flow Cytometry. For FACS analysis, cells were washed
with PBS to remove nonadherent cells and harvested mech-
anically. After ﬁxation with 4% formaline for 10min,
cells were incubated with antibodies against CD14, CD45,
CD90, or CD105 for 40min at ambient temperature. Cor-
responding isotype controls were used according to standard4 The Scientiﬁc World Journal
Table 1: Sequences of used primer pairs and gen bank accession number of target genes.
Gene Gene bank
accession number Forward primer 5  →3  Reverse primer 5  →3  Annealing
temperature
Amplicon
size [bp]
GAPDH NM 002046.3 GTCAGTGGTGGACCTGACCT AGGGGTCTACATGGCAACTG 58◦C 419bp
CD34 NM 001025109 AGAAAGGCTGGGCGAAGACCC AGTGGGGAAGGGTTGGGCGT 56◦C 311bp
Collagen Type 1 NM 000088.3 CAGCCGCTTCACCTACAGC TTTTGTATTCAATCACTGTCT-
TGCC 56◦C8 4 b p
Runx2 NM 001015051.3 TGCCTAGGCGCATTTCAGGTGC GGTGGTGGTGCATGGCGGAA 58◦C 359bp
Osterix NM 152860 CCCAGGCAACACTCCTACTC GGCTGGATTAAGGGGAGCAAA 62◦C 175bp
Osteonectin NM 003118 AGCACCCCATTGACGGGTA GGTCACAGGTCTCGAAAAAGC 60◦C 105bp
Osteopontin NM 000582 CTCCATTGACTCGAACGACTC CGTCTGTAGCATCAGGGTACTG 60◦C 257bp
Osteocalcin NM 199173.3 ATGAGAGCCCTCACACTCCTC GCCGTAGAAGCGCCGATAGGC 62◦C 294bp
Bone
sialoprotein NM 004967 TGACTCATCCGAAGAAAATGG-
AG CTGGATTGCAGCTAACCCTGT 60◦C 202bp
Alkaline
phosphatase NM 000478.4 ACGTGGCTAAGAATGTCATC CTGGTAGGCGATGTCCTTA 53◦C 475bp
Matrix Gla
Protein NM 000900 AGATGGAGAGCTAAAGTCCAA-
GA GTAGCGTTCGCAAAGTCTGTA 60◦C 102bp
Osteoblast
speciﬁc factor 2 NM 006475 TAAGTTTGTTCGTGGTAGCACC GTGTGGGTCCTTCAGTTTTGATA 60◦C 140kb
BMP2 NM 001200 CCCCCTACATGCTAGACCTGT CACTCGTTTCTGGTAGTTCTTCC 60◦C 150kb
BMP4 NM 130851 TGGTCTTGAGTATCCTGAGCG GCTGAGGTTAAAGAGGAAACGA 60◦C 130kb
RANKL NM 033012.3 TCCCAAGTTCTCATACCCTGA CATCCAGGAAATACATAACAC-
TCC 56◦C 245bp
Osteoprote-grin NM 002546.3 CCGGAAACAGTGAATCAACTC AGGTTAGCATGTCCAATGTG 60◦C 313bp
protocols. Measurement was performed in a FACSCanto II
(BD, Germany). Data were evaluated employing FlowJo soft-
ware (Tree Star, USA).
2.16. Statistics. Results are shown as column graphs showing
the mean ± standard error of the mean (SEM). Datasets
were compared by one-way analysis of variance followed by
Bonferoni’s multiple comparison test (GraphPad Prism Soft-
ware,ElCaminoReal,USA).P<0.05wastakenasminimum
level of signiﬁcance.
3. Results
3.1. MOMPs and PCMOs Show a Comparable Phenotype.
Isolation of peripheral blood monocytes by gradient cen-
trifugation and subsequent selection by adhesion resulted in
approximately 60% CD14 and over 95% CD45 positive cells
inFACSanalysis(datanotshown).Bothtreatmentstoobtain
MOMPs and PCMOs from peripheral blood monocytes
have a remarkable impact on the proliferation capacity of
adherent cells. After 6 days of culture, PCMOs show signi-
ﬁcantly higher cell viability in comparison to untreated mo-
nocytes and MOMPs (Figure 1(a)).
Under both culture conditions to obtain MOMPs and
PCMOs, as well as in the untreated control cells, two dif-
ferent cell morphologies were observed: one spindle-shaped,
elongated form and a set of ﬂattened, round cells. Here,
the treatment to obtain PCMOs resulted in a population
mainly consisting of the ﬂattened, round phenotype after 6
days of culture, whereas MOMPs and untreated monocytes
appeared as a mixed population with a considerable part of
cells showing a spindle-shaped appearance.
On day 6 after isolation, MOMPs, PCMOs and untreated
control monocytes were investigated for expression of hema-
topoietic markers CD14, CD34, CD45, CD68, and mes-
enchymal markers CD90, CD105, and collagen type 1.
Interestingly, the testing of the mentioned markers
revealedthatMOMPsandPCMOsshareasimilarphenotype
with untreated control monocytes cultivated for the same
time period. On day 6 all cell types express the markers
CD14, CD45, CD90, and CD105 detected by ﬂow cytometry
(Table 2). In addition, all groups expressed similar levels
of collagen type 1 and the hematopoietic stem cell marker
CD34 (Figure 1). Immunostaining of MOMPs, PCMOs, and
control monocytes showed that all of these were positive for
the monocyte marker CD 68 (Figure 2).
3.2. MOMPs and PCMOs Show Weak Response to Diﬀerentia-
tion Treatment Regarding Osteogenic Markers. To investigate
the osteogenic potential of MOMPs and PCMOs, conﬂuent
cultures of both cell types were treated with osteogenic stan-
dard diﬀerentiation medium containing dexamethasone. We
recognized a strong apoptotic eﬀect of the dexamethasone-
containing medium on all cultures, resulting in a decrease
of cell number by more than 60% during 14 days and
completecelldeathafter28daysoftreatment.Substitutionof
dexamethasonewithvitaminDavoidedthesenegativeeﬀects
on cell viability completely (data not shown). Consequently,
we used vitamin-D-containing medium for the following
diﬀerentiation experiments.The Scientiﬁc World Journal 5
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Figure 1: Treatments to obtain PCMOs and MOMPs inﬂuence proliferation and expression of monocytes. (a) Human mononuclear cells
(N = 4, n = 3) were cultivated without speciﬁc treatment (Mo), treated for 6 days to obtain MOMPs (M) or PCMOs (P). Viability was
measured by Alamar blue assay on day 6. P shows a signiﬁcantly higher viability than Mo (∗∗∗P<0.001). (b) Relative expression levels of
CD34 measured by RT-PCR normalized to GAPDH and subsequently to expression of CD34 in nonadherent bone marrow cells (naBMCs)
as internal control (N = 3, n = 3). Mo and M show a signiﬁcantly higher expression of CD34 on day 6 than Mo on day 1 (∗∗P<0.01;
∗∗∗P<0.001). After osteogenic diﬀerentiation, CD34 levels in Mo decreased signiﬁcantly in comparison to Mo on day 6 (◦◦P<0.05). (c)
Relative expression levels of collagen type 1 measured by RT-PCR normalized to GAPDH and subsequently to expression of collagen type
1 in primary osteoblasts (O) as internal control (N = 3, n = 3). Mo, M and P show expression of low levels of collagen type 1 on all days
(∗∗∗P<0.001). Monocytes (Mo) day 1: freshly isolated monocytes; Mo, MOMP (M), and PCMO (P) day 6: cells after treatment; Mo, M, P
day 20: cells after diﬀerentiation with vitamin D containing medium.
Table 2: Phenotype of monocyte-derived cells. Numbers indicating percentage of positive cells ± standard error of the mean (SEM)
measured by FACS analysis from 3 independent donors.
Monocytes 6
days
MOMPs 6
days
PCMOs 6
days
Monocytes
20 days
MOMPs 20
days
PCMOs 20
days Osteo-blasts
CD14 11,16 ± 0,77 16,37 ± 8,62 33,62 ± 5,41 9,97 ± 1,83 19,69 ± 2,49 22,92 ± 7,69 3,52 ± 3,04
CD45 93,71 ± 4,29 85,72 ± 7,52 98,60 ± 0,45 85,59 ± 10,97 91,77 ± 6,29 97,49 ± 0,72 0,61 ± 0,36
CD90 19,83 ± 13,43 35,53 ± 17,76 32,24 ± 16,13 26,80 ± 21,02 16,98 ± 13,70 9,51 ± 4,38 96,35 ± 1,76
CD105 82,87 ± 10,56 86,29 ± 4,83 96,38 ± 0,91 69,44 ± 5,73 55,67 ± 13,12 61,85 ± 8,28 94,77 ± 1,786 The Scientiﬁc World Journal
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Figure 2: Diﬀerentiated monocytes (Mo), MOMPs (M), and PCMOs (P) express CD68. Representative picture of immunohistochemistry
againstCD68inMo,M,andP(N = 3,n = 3).AftertreatmenttoobtainMOMPsandPCMOs(“day6;”ﬁrstcolumn)allcelltypesarepositive
for CD68. 20 days after the diﬀerentiation—either with vitamin D (column 2) or dexamethasone (column 3)—cells also expressed CD68,
while primary osteoblasts proved to be negative for CD68. Magniﬁcation 200x. Following diﬀerentiation with vitamin D, high numbers of
giant cells (marked with →) appear. Macrophage-like cells are marked with ⇒.
To exclude beneﬁcial eﬀects of dexamethasone towards
vitamin D regarding osteogenic diﬀerentiation, all diﬀeren-
tiation experiments described below were performed with
dexamethasone-containing diﬀerentiation medium in paral-
lel. Here, dexamethasone showed no advantage towards vita-
min-D-containing medium in any diﬀerentiation experi-
ment (data not shown).
Treatment of MOMPs, PCMOs, and control monocytes,
with diﬀerentiation media, resulted in the appearance of
multinuclear giant cells. These represented a third pheno-
type, besides the persistent spindle-shaped and the elongated
cells. Giant cells were found more frequently in cell popu-
lations treated with vitamin D than in those treated with
dexamethasone-containing diﬀerentiation medium. They
appeared in larger number in PCMO rather than in MOMP
populations and in control monocytes and their number
strongly varied among diﬀerent donors. In some donors,
they represented the major cell type after the diﬀerentiation
procedure (Figure 2; giant cells marked with →).
For investigation of alkaline phosphatase (AP), activity
and production of mineralized matrix functional tests were
performed. These are the most widely used markers to
conﬁrm osteogenic diﬀerentiation. Here, the diﬀerentiation
procedure resulted in an increase in AP activity in both
MOMPs and PCMOs, as well as in control monocytes. The
achieved AP activity is low if compared to that of primary
human osteoblasts (Figure 3(a)). In comparison to pri-
mary osteoblasts, MOMPs, PCMOs, and control monocytes
produce minimal amounts of mineralized matrix after dif-
ferentiation procedure (Figure 3(b)).The Scientiﬁc World Journal 7
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Figure 3: Weak response of monocyte-derived cells to diﬀerentiation. (a) Alkaline phosphatase (AP) activity [μmol/min] of monocyte-
derived cells in comparison to primary osteoblasts, macrophages, and osteoclasts (N = 4, n = 3). AP activity [μM/min] normalized to cell
amount determined by Alamar blue. (b) Alizarin red measurement [μmol] in monocyte-derived cells in comparison to primary osteoblasts
(N = 4, n = 3). (c) Relative expression levels of Runx2 measured by RT-PCR normalized to GAPDH and subsequently to expression
in primary osteoblasts as internal control (N = 3, n = 3). Runx2 expression signiﬁcantly increases after treatment to obtain PCMOs
(∗∗∗P<0.001). After the diﬀerentiation procedure, Runx2 expression in PCMOs decreases again (◦◦◦P<0.001) (d) relative expression
levels of Osterix measured by RT-PCR normalized to GAPDH and subsequently to expression in monocytes after 6 days in culture as
internal control (N = 3, n = 3). Osterix expression signiﬁcantly increases after treatment to obtain MOMPs and after 6 days culture of
control monocytes (∗∗∗P<0.001). After the diﬀerentiation procedure, osterix expression in both cell types decreases again (◦◦◦P<0.001).
Monocytes (Mo) day 1: freshly isolated monocytes; Mo, MOMP (M), and PCMO (P) day 6: cells after treatment; Mo, M, P day 20: cells after
diﬀerentiation with vitamin-D-containing medium. Macrophages (Ma), osteoclasts (Oc). (∗∗∗P<0.001).
After observing a moderate eﬀect of diﬀerentiation treat-
ment on AP activity, we investigated whether or not diﬀer-
entiation treatment changes the expression of the bone-re-
lated transcription factors Runx2 and osterix by RT-PCR.
As freshly isolated monocytes did not express Runx2,
diﬀerentiation treatment of MOMPs, PCMOs, and control
monocytes resulted in low Runx2 expression. However, the
highest Runx2 expression, even reaching expression levels of
primary osteoblasts, was observed in PCMOs without addi-
tional osteogenic diﬀerentiation treatment (Figure 3(c)).
Expression levels of osterix decreased in MOMPs, PCMOs,
and control monocytes after osteogenic diﬀerentiation treat-
ment to levels observed in freshly isolated monocytes
(Figure 3(d)).
The eﬀect of the diﬀerentiation procedure on osteogenic
marker gene expression was investigated by RT-PCR. As
expectedfromtheexpressionproﬁleofthetwokeyregulators
of osteogenesis (Runx2 and Osterix), the diﬀerentiation
treatment had no substantial eﬀect on expression levels of
investigated osteogenic marker genes. These ﬁndings were
similar in MOMPs and PCMOs treated with diﬀerentia-
tion medium. Noteworthy, the bone markers osteonectin,8 The Scientiﬁc World Journal
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Figure 4: Diﬀerentiation treatment did not change bone marker
expression.Expressionpatternonimportantosteoblastmarkergens
detected by RT-PCR. Freshly isolated monocytes (Mo); M and
P after treatment to obtain MOMPs and PCMOs and untreated
control cells (Mo, M, P “day 6”), after diﬀerentiation with medium
containing vitamin D (Mo, M, P “day 20 Vit. D”), or with
medium containing dexamethasone (Mo, M, P “day 20 Dexa”);
controls: macrophages (Ma), osteoclasts (Oc), primary osteoblasts
(O), mesenchymal stem cells (MSC), nonadherent bone marrow
cells (naBMC), and negative control (N). (N = 3, n = 1).
osteopontin, and osteocalcin are already expressed at similar
levels before diﬀerentiation treatment in MOMPs, PCMOs,
freshly isolated monocytes, and untreated cultured mono-
cytes (Figure 4).
3.3. Hematopoietic Cell Markers Persist during Dediﬀeren-
tiation and Diﬀerentiation Procedure. As full transdiﬀeren-
tiation of monocytes into osteoblasts would also include
losing hematopoietic markers, we were investigating if the
diﬀerentiation treatment shows an impact on the expression
of surface markers. Here, the osteogenic diﬀerentiation did
not result in the loss of CD14 and CD45 expression, whereas
m a r k e r so fn o n m a t u r a t e dh e m a t o p o i e t i cc e l l ss u c ha sC D 3 4
and CD90 decrease during the diﬀerentiation procedure
(Figure 1(b), Table 2). Immunohistochemistry revealed that
diﬀerentiated MOMPs, PCMOs, and control monocytes are
positive for the monocyte marker CD68. The persistence of
CD68andthecellstypicalmorphologyidentiﬁestheserather
as macrophages than as diﬀerentiated osteoblast-like cells
(Figure 2; macrophage like cells marked with ⇒).
To investigate if the observed giant cells represent foreign
body giant cells or osteoclasts, we performed TRAP staining.
Here, the strongly positive staining clearly identiﬁed these
cells as osteoclasts (Figure 5(a); osteoclasts marked with →).
3.4. Activation of Monocytes Promotes Alkaline Phosphatase
Activity. To investigate if the observed increase of AP activity
in monocytes, MOMPs, and PCMOs during the diﬀer-
entiation procedure is a sign of monocyte activation and
maturation into macrophages or osteoclasts, rather than
of osteogenic transdiﬀerentiation, we examined the activity
of alkaline phosphatase in macrophages and osteoclasts.
Here, alkaline phosphatase activity in macrophages showed
similar levels to monocytes, MOMPs, and PCMOs after the
osteogenic diﬀerentiation procedure. In contrast, matura-
tion into osteoclasts did not substantially alter AP activity
(Figure 3(a)).
To conﬁrm the positive correlation between monocyte
activationandincreaseinAPactivity,weactivatedPCMOs—
which reach the highest AP levels after diﬀerentiation
treatment—by treatment with fetal calf serum (FCS). Here,
the cultivation in presence of fetal calf serum leads to higher
levels of proinﬂammatory cytokines TNF-alpha, TGF-beta,
and RANKL in the cultures in comparison to cultivation
in autologous serum. This indicates higher activation of
the cells. Thereby, higher cell activation was accompa-
nied with distinctly higher activity of alkaline phosphatase
(Figure 5(c)).
4. Discussion
Diﬀerentiation of monocytes into osteoblasts would repre-
sent a transdiﬀerentiation process, which is deﬁned as con-
version of a diﬀerentiated cell type into another type of
fullydiﬀerentiatedcells.Transdiﬀerentiationintobonetissue
is a naturally occurring phenomenon, reported as meta-
plasia. Ectopic bone formation quite frequently occurs in
scar tissue, in muscle after repeated trauma, and in walls of
sclerotic arteries [15]. Usually, the transdiﬀerentiation pro-
cess includes a dediﬀerentiation and a rediﬀerentiation step
[16]. In case of monocytes, several treatment options are
reported to shift these cells into a stem cell-like cell type, able
to diﬀerentiate into various cell types [7, 9, 17, 18]. Investi-
gation of suitability of monocytes as sources for generation
of osteoblasts was performed on MOMPs and PCMOs, two
reported cell types obtained from monocytes that can trans-
diﬀerentiate into mesenchymal cell types. Both cell types are
described as cells with a unique phenotype. While MOMPs
are characterized by combined expression of CD14, CD45,
CD105,CD34,andtypeIcollagen,PCMOsshowacombined
expressionofCD14,CD45,lowlevelsofCD34,andCD90[4,
10]. However, our study revealed that MOMPs additionally
expressed CD90, while PCMOs were positive for CD105.
Therewith both cell types were indistinguishable regarding
the investigated markers and did not even diﬀer substantially
from untreated control monocytes after 6 days of culture.
The dediﬀerentiation process from monocytes towards
PCMOs was characterized in more detail. Ungefroren et al.
conﬁrmed a change of the monocytes phenotype towards a
more stem-cell-like appearance during a 6-day dediﬀerentia-
tion treatment. The cells downregulated some monocyte-de-
ﬁning gens and startedtoexpress stemcellmarkers overtime
[19]. Recently, our group demonstrated that dediﬀerentia-
tion of monocytes towards PCMOs with subsequent hep-
atogenic diﬀerentiation can be signiﬁcantly improved by the
use of the patient’s autologous serum instead of human
AB serum or fetal calf serum (FCS) [3]. However, within
the present study, we could neither detect a positive nor a
negative impact on susceptibility of PCMOs towards osteo-
genic diﬀerentiation by using autologous serum instead of
either FCS or human AB serum during dediﬀerentiation
treatmentand/orsubsequentosteogenicdiﬀerentiation(dataThe Scientiﬁc World Journal 9
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Figure 5: Diﬀerentiation procedure activates and maturates monocytes. TRAP staining of giant cells (marked with →) occurring after
diﬀerentiation treatment of PCMOs with medium containing vitamin D (a) and osteoclasts (b); magniﬁcation 200x. (c) Comparison of
Alkaline phosphatase [μmol/min]-, TNF-alpha [pg/mL]-, TGF-beta [pg/mL], and RANKL-[pg/mL] levels normalized to SRB in PCMOs
either isolated and diﬀerentiated in medium containing fetal calf or autologous serum (N = 5, n = 3). Diﬀerentiation performed with
osteogenic medium containing vitamin D (∗P<0,05; ∗∗∗P<0.001).
not shown). Moreover, our data suggest that although cells
were treated towards MOMPs they undergo spontaneous
partialdediﬀerentiationduringa6daycultureperiodandare
ﬁnally comparable to PCMOs. Both cell types show down-
regulationofCD14andupregulationofthestemcellmarkers
CD34, CD90, and CD105 compared to freshly isolated mo-
nocytes [7, 9]. It is noteworthy that even untreated control
monocytes undergo partial dediﬀerentiation during in vitro
culture. This raises the question if dediﬀerentiation of
PCMOs and MOMPs is dependent on a speciﬁc treatment
onlyorrathertheresponsetoinvitrocultureconditions[20].
Thegeneralacceptedhypothesisofthemolecularmecha-
nismoftransdiﬀerentiationisthechangeinactivityofamas-
terswitchgene,whosenormalfunctionistodistinguishboth
tissues in development [16]. In case of bone, Runx2 is associ-
ated as a master regulatory gene known to control most bone
speciﬁc gene expression [21]. To fulﬁll criteria of transdiﬀer-
entiation, this switch of master gene activity is paralleled by
phenotypicalcellchangeswiththelossofitsoriginalmarkers
and the adoption of the markers of the new cell phenotype
[15]. When we investigated the response of the monocyte-
derived cells to osteogenic diﬀerentiation, the osteogenic
medium failed to induce expression of osteogenic transcrip-
tion factors and bone-related marker genes. Furthermore, it
failed to induce production of detectable amounts of min-
eralized matrix. Instead of a phenotypic cell change towards
an osteoblast phenotype, the hematopoietic surface markers
CD14, CD45 andCD68 persisted during this cultureprocess.
Noteworthy, our study revealed that expression of osteo-
nectin, osteopontin, and osteocalcin—which was used in
several studies to conﬁrm osteogenic transdiﬀerentiation of
monocytes—is already expressed in freshly isolated mono-
cytes [9, 17]. It is well known that osteopontin and osteo-
nectin are expressed in various tissues [22, 23]. Furthermore,
osteocalcin, which is known to be one of the most speciﬁc
bone markers, is expressed in adipose and vascular tissues as
well as in diﬀerentiated monocytes [24–26]. These ﬁndings
underline that the expression of some apparently typical, but
not tissue-speciﬁc markers does not necessarily imply the
diﬀerentiation status of a cell. The diﬀerentiation of a cell is10 The Scientiﬁc World Journal
rather determined by unique expression pattern of a variety
genes, which—considered separately—are not necessarily
speciﬁc for one tissue [27]. Similarly, the appearance of
alkaline phosphatase activity does not require transdiﬀer-
entiation into osteoblasts, as this enzyme occurs in various
tissues apart from bone, including myeloid cells such as
neutrophil granulocytes and dendritic cells [28]. It is known
that monocyte-derived granuloma cells are positive for
bone-speciﬁc alkaline phosphatase in vivo and that alkaline
phosphatase is expressed during monocyte diﬀerentiation in
vitro[26, 29]. Our present work conﬁrms that maturation of
monocytesintomacrophagesisaccompaniedbyanincreased
expression and activity of alkaline phosphatase. The sponta-
neous transformation of monocytes into osteoclasts in vitro
is a well-known phenomenon [30, 31]a sw e l la si t sa l k a l i n e
phosphatase expression [26]. Our data conﬁrms expression
of alkaline phosphatase in osteoclasts on RNA level, yet it
does not lead to measurable alkaline phosphatase activities
in the cells.
When MOMPs and PCMOs were treated with osteogenic
medium [9, 17] —we observed a strong apoptotic eﬀect in
thesecells.This,however,ismostlikelylinkedtothepresence
of dexamethasone, which is known to trigger apoptosis [32].
In contrast, osteogenic diﬀerentiation medium containing
vitamin D as substitute for dexamethasone did not inﬂuence
cellviabilitynegatively[33].However,bothusedmediafailed
to induce a proper osteogenic transdiﬀerentiation in mo-
nocytes.Ofcourse,wecannotruleoutthatmonocytesinhere
a transdiﬀerentiation capacity towards osteoblasts using a
more potent osteogenic medium.
It is likely that both supplements—dexamethasone and
vitamin D—have diﬀerent eﬀects on monocytes as on
mesenchymal stem cells and osteoblasts. Both substances
show beneﬁcial eﬀects in myeloproliferative disorders. While
dexamethasone leads to apoptosis, vitamin D promotes mat-
uration of undiﬀerentiated monocytes [34]. Thereby, vita-
min D seems to favor maturation of monocytes into osteo-
clasts[35].Thisisinlinewithourﬁndings,aswehavedetect-
ed more osteoclasts after vitamin D treatment rather than
after dexamethasone incubation and a decrease of stem cell
markers CD34 and CD90 after treatment with both sub-
stances.
Summarizing our ﬁndings, we must conclude that we
could not conﬁrm inherent potential for osteogenic trans-
diﬀerentiation of monocytes in our experimental setting. It
seems more likely that the observed change of the cells in
response to treatment towards PCMOs and MOMPs and
subsequent diﬀerentiation procedure represents usual events
in monocyte biology of maturation towards macrophages
and osteoclasts. Of course, we cannot rule out that cells from
monocytic origin have a potential to transdiﬀerentiate into
other cell types—including osteoblasts—in response to spe-
ciﬁc stimuli.
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